Fundraising Fox
Ourobio
Indianapolis, US · Founded 2020 · 2 employees on LinkedIn · 1 known investors
Find your way into Ourobio
Sign up to see every warm intro you have to Ourobio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ourobio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ourobio develops engineered microorganisms that convert industrial byproducts into biomaterials using synthetic biology. The company targets industries seeking sustainable alternatives to petroleum-derived chemicals and materials.
Founders & leadership
Ourobio was founded in 2020 by Alec Brewer and Kobe Rogers.
AB
Alec BrewerFounder & Chief Executive OfficerAlec Brewer is founder and CEO of Ourobio, which develops engineered microorganisms to convert industrial byproducts into sustainable biomaterials using synthetic biology.
KR
Kobe RogersFounder & Chief Operations OfficerKobe Rogers has experience in laboratory operations, R&D, and computational and molecular biology. He has led research teams, managed grants and secured non-dilutive funding, and contributed to process optimization and compliance frameworks in biotech.
Investors · 1
Related companies · 2
Ouro MedicinesOuro Medicines is a biotechnology company developing cell-depleting therapies aimed at resetting the immune system to treat chronic immune-mediated diseases such as autoimmune and autoinflammatory conditions. It is advancing a pipeline of biologics and small molecules across immunology and related therapeutic areas.
SurfSurf Bio is a preclinical biopharmaceutical company developing its SnapShot technology, which uses a proprietary polymer to create ultra-high-concentration antibody and biologic formulations (600+ mg/mL, doses over 1,000 mg) for delivery via a standard autoinjector. The technology enables at-home subcutaneous self-injection of monoclonal antibodies and biologics as an alternative to in-clinic IV infusion, and is offered to pharmaceutical API manufacturers through partnerships.
Companies working in the same space as Ourobio.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Environmental Protection Agency (EPA) | Phase I | 2023 | $100K |
| Environmental Protection Agency (EPA) | Phase I | 2021 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Ourobio do?
- Ourobio develops engineered microorganisms that convert industrial byproducts into biomaterials using synthetic biology. The company targets industries seeking sustainable alternatives to petroleum-derived chemicals and materials.
- Who founded Ourobio?
- Ourobio was founded by Alec Brewer, Kobe Rogers in 2020.
- Who are Ourobio's investors?
- Ourobio's investors include Lighthouse Network Ventures Llc.
- Where is Ourobio headquartered?
- Ourobio is headquartered in Indianapolis, US.